Analyst: Too soon to write them off
A stock market analyst from Jyske Bank believes Neurosearch has 7-8 months to secure the capital needed for survival. It looks difficult, he says, but it is too soon to write them off completely.
According to stock market analyst Frank H. Andersen, last week’s announcement from Neurosearch that the company was writing down the key project Huntexil to 0 is a direct consequence of the company’s inability to secure a partnership deal or any other type of fundraising.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler:
Neurosearch writes down the value of Huntexil to 0
For abonnenter
